网络出版日期: 2021-06-29
基金资助
上海市卫生和计划生育委员会科研课题(201840083);上海市卫生和计划生育委员会重要薄弱学科建设计划(2015ZB0503);上海市高校产学研课题(RC20190079)
Exploratory study on downregulation of PD-L1 in KRAS G12V-mutant non-small cell lung cancer cells by selumetinib
Online published: 2021-06-29
Supported by
Scientific Research Project of Shanghai Municipal Commission of Health and Family Planning(201840083);Weak Discipline Construction Project of Shanghai Municipal Commission of Health and Family Planning(2015ZB0503);Production, Study and Research Project of Shanghai Colleges and Universities(RC20190079)
目的·探究不同Kirsten大鼠肉瘤病毒癌基因（Kirsten rat sarcoma viral oncogene，KRAS）突变型非小细胞肺癌（non-small cell lung cancer，NSCLC）患者肿瘤组织及细胞系与程序性死亡蛋白配体1（programmed cell death ligand 1，PD-L1）表达的关系及其可能的调控机制。方法·通过实时荧光定量PCR和荧光活化细胞分选法，在NSCLC细胞系中验证PD-L1 mRNA和蛋白的表达与KRAS突变状态的关系。通过免疫组织化学法检测77例早期（Ⅰa~Ⅱb期）NSCLC患者肿瘤组织中PD-L1的表达情况。通过Western blotting研究KRAS突变对RAS下游信号通路分子蛋白激酶B（protein kinase B，PKB，又称为AKT）、哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin，mTOR）、核糖体S6蛋白激酶（ribosomal S6 protein kinase，p70S6K）、细胞外调节蛋白激酶（extracellular regulated protein kinase，ERK）的影响。用RAF抑制剂达拉非尼、有丝分裂原活化蛋白激酶（mitogen activated-protein kinase，MEK）抑制剂司美替尼、磷脂酰肌醇3-激酶抑制剂GDC0941、AKT抑制剂MK2206和mTOR抑制剂雷帕霉素分别处理6个KRAS突变NSCLC细胞株，检测这5种酪氨酸激酶抑制剂对PD-L1表达的调控作用。结果·在NSCLC细胞系中，KRAS突变细胞系的PD-L1 mRNA和蛋白的表达水平均显著高于KRAS野生型细胞系（均P<0.05），且KRAS G12V细胞系PD-L1的mRNA表达水平最高，KRAS G12C细胞系PD-L1的蛋白表达水平最高。对于早期NSCLC患者，PD-L1在KRAS G12V和G12D突变型患者肿瘤组织中高表达的比例显著高于KRAS野生型。Western blotting结果显示，KRAS突变NSCLC细胞系中，p70S6K被激活，而ERK、AKT、mTOR未被激活。进一步研究发现，1 μmol/L GDC0941、0.5 μmol/L MK2206和10 nmol/L雷帕霉素均未对6个KRAS突变NSCLC细胞株的PD-L1表达产生影响，5 nmol/L达拉非尼仅在1个KRAS G12V突变株和1个KRAS L19F突变株引起PD-L1表达上调（均P<0.05），而0.1 μmol/L司美替尼在3个KRAS G12V突变株和1个KRAS L19F突变株引起PD-L1表达下调（均P<0.05），且呈一定剂量依赖性。结论·KRAS突变，尤其是G12V突变型的NSCLC细胞或组织的PD-L1表达水平明显高于KRAS野生型；司美替尼可下调KRAS G12V突变型NSCLC细胞的PD-L1水平，推测KRAS G12V突变的NSCLC细胞可能通过上调MEK上调PD-L1的表达。
关键词： KRAS突变; 非小细胞肺癌; 免疫治疗; 程序性死亡蛋白配体1; 司美替尼
马韵芳 , 潘丽娜 , 李圳 , 高蓓莉 , 胡家安 , 徐志红 . 司美替尼下调KRAS G12V突变型非小细胞肺癌细胞PD-L1水平的探索性研究[J]. 上海交通大学学报（医学版）, 2021 , 41(6) : 741 -748 . DOI: 10.3969/j.issn.1674-8115.2021.06.006
·To investigate the correlation between Kirsten rat sarcoma viral oncogene(KRAS)-mutant subtypes and programmed cell death ligand 1 (PD-L1) expression in the non-small cell lung cancer (NSCLC) tissues and cell lines, and the possible underlying mechanism.
·Real-time quantitative PCR and fluorescence-activated cell sorting were used to verify the correlation between PD-L1 mRNA or protein and KRAS mutation status in the NSCLC cell lines. Immunohistochemistry was used to detect the expression of PD-L1 in the tumor tissues of 77 NSCLC patients with early stages (Ⅰa?Ⅱb). The effect of KRAS mutation on the cytokines in the RAS downstream signaling pathway, i.e., protein kinase B (PKB or AKT), mammalian target of rapamycin (mTOR), ribosomal S6 protein kinase (p70S6K), and extracellular regulated protein kinase (ERK), was studied by Western blotting. Dabrafenib (RAF inhibitor), selumetinib [mitogen activated-protein kinase (MEK) inhibitor], GDC0941 (phosphoinositide 3-kinase inhibitor), MK2206 (AKT inhibitor), and rapamycin (mTOR inhibitor) were used to treat 6 KRAS-mutant cell lines, respectively, to detect the regulation of these five tyrosine kinase inhibitors on PD-L1 expression.
·In the NSCLC cell lines, the expressions of PD-L1 mRNA and protein in the KRAS mutant cell lines were significantly higher than those in the KARS wild-type cell lines (P<0.05). KRAS G12V- and G12C-mutant cell lines showed the highest expression of PD-L1 mRNA and protein, respectively. For the NSCLC patients with early stages, the proportions of PD-L1 overexpression in the tumor tissues of the patients with KRAS G12V and G12D mutants were significantly higher than those of the patients with KRAS wild-type. Western blotting showed that in the KRAS-mutated NSCLC cell lines, p70S6K was activated, while ERK, AKT and mTOR were not activated. Moreover, 1 μmol/L GDC0941, 0.5 μmol/L MK2206, and 10 nmol/L rapamycin could not affect the expression of PD-L1 in the 6 KRAS-mutant cell lines. Darafenib (5 nmol/L) up-regulated PD-L1 in only one KRAS G12V-mutant cell line and one L19F-mutant cell line (P<0.05), while selumetinib (0.1 μmol/L ) inhibited the expressions of PD-L1 in three KRAS G12V-mutant cell lines and one L19F-mutant cell line (P<0.05) in a dose-dependent manner.
·The expressions of PD-L1 in the tumor tissues and cell lines of NSCLC with KRAS mutation, especially G12V mutation subtype, were higher than those in the NSCLC tissues and cell lines with KRAS wild-type. Selumetinib can downregulate the expression of PD-L1 in KRAS G12V-mutant NSCLC cells, which suggests that KRAS G12V-mutant NSCLC cells may up-regulate the expression of PD-L1 by upregulating MEK.
| 1 | Rothschild SI. Targeted therapies in non-small cell lung cancer: beyond EGFR and ALK[J]. Cancers (Basel), 2015, 7(2): 930-949. |
| 2 | Seigel RL, Miller KD, Jemal A, et al. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. |
| 3 | Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. |
| 4 | Renaud S, Falcoz PE, Scha?ffer M, et al. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases[J]. Br J Cancer, 2015, 113(8): 1206-1215. |
| 5 | Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135. |
| 6 | Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639. |
| 7 | Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(25): 2980-2987. |
| 8 | Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35): 3924-3933. |
| 9 | Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920-1928. |
| 10 | Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550. |
| 11 | Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030): 1837-1846. |
| 12 | Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review[J]. Oncotarget, 2017, 8(29): 48248-48252. |
| 13 | Lan B, Ma C, Zhang C, et al. Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis[J]. Oncotarget, 2018, 9(7): 7684-7699. |
| 14 | Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(3): 300-311. |
| 15 | Lococo F, Torricelli F, Rossi G, et al. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas[J]. Lung Cancer, 2017, 113: 93-101. |
| 16 | Gridelli C, Ardizzoni A, Barberis M, et al. Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology[J]. Transl Lung Cancer Res, 2017, 6(3): 373-386. |
| 17 | Lastwika KJ, Wilson W, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer[J]. Cancer Res, 2016, 76(2): 227-238. |
| 18 | Lee MH, Yanagawa J, Tran L, et al. FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells[J]. Am J Transl Res, 2020, 12(2): 409-427. |
| 19 | Cavazzoni A, Digiacomo G, Alfieri R, et al. Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer[J]. Cancers (Basel), 2020, 12(3): 666. |
| 20 | Chen MC, Pangilinan CR, Lee CH. Salmonella breaks tumor immune tolerance by downregulating tumor programmed death-ligand 1 expression[J]. Cancers (Basel), 2019, 12(1): 57. |
| 21 | Chang HL, Kuo YH, Wu LH, et al. The extracts of Astragalus membranaceus overcome tumor immune tolerance by inhibition of tumor programmed cell death protein ligand-1 expression[J]. Int J Med Sci, 2020, 17(7): 939-945. |
| 22 | Deng L, Qian G, Zhang S, et al. Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation[J]. Oncogene, 2019, 38: 6270-6282. |
/
| 〈 |
|
〉 |